1 published article · Updated continuously
11 trials tracked for vasomotor symptoms: 7 in phase 3 or 4 and 1 with published results. The most-cited published study has 2 citations.
Showing the 11 most-cited and recently-updated of 11 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
Estetrol oral tablet demonstrated a significant reduction in the mean weekly frequency of moderate to severe vasomotor symptoms (VMS) from baseline at both week 4 and week 12 (p=0.0436) 1. However, no statistically significant change was observed in the severity of these symptoms for this intervention (p=0.7786) 1.
Desvenlafaxine succinate SR significantly reduced both the average daily number and the average daily severity of moderate to severe hot flushes at week 4 and week 12 (p<0.001) 7. Additionally, desvenlafaxine was evaluated for safety parameters including nausea during the first two weeks and DESS total scores during tapering 6.
The combination of 0.5mg DRSP / 0.5mg E2 significantly reduced the weekly frequency of moderate to severe hot flushes at week 4 (p<0.0001) and week 12 (p<0.0001), as well as the weekly mean daily severity of these symptoms 5.
Esmirtazapine showed a statistically significant reduction in the average daily frequency of moderate/severe VMS at week 4 (p<0.01) and an increase in severity scores at week 4 (p<0.01); however, the change in frequency at week 12 did not reach statistical significance (p=0.08) 3. A separate trial for esmirtazapine showed a reduction in average daily frequency of VMS at week 4 (p<0.01), but results at week 12 were not statistically significant (p=0.06) and there was no significant change in severity 4.
AI synthesis of 8 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
